TFPI Inhibitor Peptide Complexes for Hemophilia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for blood coagulation disorders, such as hemophilia, require frequent and costly intravenous infusions of clotting factors, which are often ineffective due to antibody formation, and there is a need for alternative compositions and methods to enhance thrombin formation and blood clotting.
Innovation Solution
Development of peptide complexes that bind to Tissue Factor Pathway Inhibitor (TFPI), inhibiting its inhibitory activity and enhancing thrombin generation, even in the absence of certain clotting factors, by administering a peptide or peptide complex that binds to multiple TFPI epitopes, thereby improving blood clot formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If factor replacement therapy is used to treat hemophilia, then blood clotting function is restored, but treatment requires frequent intravenous infusions which are costly, time-consuming, and lose efficacy due to antibody formation
Solution Approach 1:
The patent uses TFPI inhibitors as intermediary substances that block the action of Tissue Factor Pathway Inhibitor, thereby enhancing thrombin generation and blood clotting without requiring clotting factor replacement. This mediator approach bypasses the antibody formation problem associated with factor replacement therapy while achieving the desired therapeutic effect of improved coagulation function
Solution Approach 2:
The patent changes the therapeutic parameter from replacing clotting factors to inhibiting TFPI activity. By administering TFPI inhibitors that bind to multiple TFPI epitopes, the therapy shifts the mechanism of action from substrate replacement to enzymatic inhibition, thereby improving therapeutic efficacy and reducing treatment frequency
2Reliability
If factor replacement therapy is administered, then clotting function is improved, but treatment cost and complexity increase due to frequent clinical setting requirements
Solution Approach 1:
TFPI inhibitors serve as intermediary agents that simplify the treatment protocol by targeting a single inhibitory pathway (TFPI) rather than requiring complex factor replacement regimens. This approach reduces treatment complexity while maintaining reliable clotting function improvement
Solution Approach 2:
The TFPI inhibitor is designed to bind to multiple TFPI epitopes simultaneously, providing multi-functional inhibition that enhances thrombin generation through a single agent. This universal approach replaces the need for multiple factor infusions and simplifies the treatment protocol
3Reliability
If traditional factor replacement therapy is used, then bleeding disorders are treated, but therapeutic efficacy diminishes upon formation of inhibitory antibodies
Solution Approach 1:
By using TFPI inhibitors as intermediaries rather than clotting factors, the therapy avoids direct exposure to the immune system that would trigger antibody formation. The inhibitor targets the TFPI protein rather than clotting factors, bypassing the harmful antibody response while maintaining therapeutic efficacy
Solution Approach 2:
The patent converts the harmful effect of TFPI (which inhibits coagulation) into a benefit by using TFPI inhibitors to block its action. This approach transforms the natural inhibitory pathway into a therapeutic opportunity, improving clotting function without the harm of antibody formation associated with factor replacement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide complexes effectively enhance thrombin formation and blood clotting in clotting factor-deficient subjects, providing a potential treatment for blood coagulation disorders with reduced frequency and cost compared to traditional therapies.
Implementation Method 1
a peptide complex that binds to at least two different TFPI epitopes and, optionally, inhibits at least two functions of TFPI
Data Source
AI summary
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.